The CINP 2026 - 37th World Congress of Neuropsychopharmacology, Glasgow, United Kingdom 26/06/2026 - 29/06/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 19.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. |
Professor Shigeto Yamawaki, former CINP President (2014–2016), passed away on June 8, 2026.
He made extraordinary contributions to neuropsychopharmacology, biological psychiatry, international scientific collaboration, and the development of CINP. His passing is a great loss not only to Japan and Asia but also to the worldwide neuropsychopharmacology community. We extend our heartfelt condolences to his family, friends, colleagues, and trainees. |
We are delighted to announce that Professor Guy Goodwin, Emeritus Professor at the University of Oxford, will deliver a keynote lecture at CINP 2026. His presentation, “Remedicalising Psychedelic Drugs for Psychiatry,” will explore the implications of his latest groundbreaking research and discuss the recently released findings that are helping to shape the future of psychedelic medicine in psychiatry. This keynote promises to provide valuable insights into one of the most exciting and rapidly evolving areas of contemporary psychiatric research. Mark your diary not to miss it: Check the full scientific program and start planning, which sessions are on your must-see list! |
We are pleased to congratulate the newly elected officers and councillors, who will officially assume their roles during the CINP 2026 Congress.
We warmly congratulate all those elected and look forward to their leadership and contributions to the global CINP community in the years ahead. We would also like to sincerely thank all candidates who stood in this election for their commitment, engagement, and willingness to serve CINP and the field of neuropsychopharmacology. |
Follow CINP on Social Media Stay connected with the latest news, research highlights, events, and updates from CINP. Join our growing global community across social media: Facebook: X (Twitter): Instagram: LinkedIn: https://www.linkedin.com/company/international-college-of-neuropsychopharmacology/ YouTube: Follow us to stay informed, engage with the community, and be part of the conversation shaping the future of neuropsychopharmacology. |
We are pleased to share a new Genomic Press Interview with Dr. Gabriella Gobbi, CINP President Elect, Professor of Psychiatry at McGill University, and Canada Research Chair in Therapeutics for Mental Health. From pioneering research on adolescent cannabis exposure and depression, to advancing novel melatonin receptor therapeutics, and early work on the neurobiology of psychedelics - Dr. Gobbi’s career exemplifies truly translational science. As the first woman elected CINP President in its 70-year history, she reflects on her journey from Italy to Canada, the clinical insights that shaped her research, and her vision for a neuropsychopharmacology that remains deeply connected to patient care. |
GLOBAL
| International Journal of Neuropsychopharmacology
Impact Factor: 3.7 |
-
March 25, 2026 08:02
-
March 20, 2026 06:20
-
January 30, 2026 10:48
